Meta Health Limited Responds to Investor Queries: Key Developments in FY2025

Overview

Meta Health Limited (“the Company”), in response to questions from the Securities Investors Association (Singapore), has provided detailed clarifications regarding its FY2025 annual report. These responses address critical issues including the underperformance of a recent acquisition, the Company’s ongoing legal proceedings, significant going concern uncertainties, and board composition deviations. Below is a comprehensive summary of the key points and their potential implications for shareholders and investors.

1. Underperformance of Jas Medical Screening Centre Acquisition

• The Group acquired Jas Medical Screening Centre Pte Ltd in November 2024. For FY2025, Jas Medical reported revenue of S\$1.36 million and expenses of S\$1.37 million, resulting in a loss of S\$9,540.
• The acquisition’s original contingent consideration was based on Jas Medical achieving a net profit after tax of at least S\$175,000 in both FY2025 and FY2026. The Company has now indicated that these targets are not expected to be met in either year.
• Key Assumptions Not Realised:
  • Assumed continued economic growth and increase in foreign worker population failed to translate into higher medical screening demand.
  • Expected cost savings from supplier volume discounts did not materialise due to lower-than-anticipated patient numbers.
• Operational Headwinds:
  • Increased competition in Jas Medical’s vicinity has eroded walk-in patient volumes and revenues.
  • Jas Medical was not selected as one of the Ministry of Manpower’s four anchor operators for the Primary Care Plan, impacting its corporate screening business.
• Turnaround Strategy:
  • Enhancing referrals from existing corporate clients in marine, construction, and F&B sectors.
  • Revising service pricing to maintain competitiveness.
  • Implementing cost-saving measures, including switching suppliers and streamlining operations.
  • No pre-existing incentive schemes for Jas Medical management, but the Company is considering introducing performance-linked incentives in future.

2. Group Growth Strategy and Funding

• Meta Health is exploring accretive business opportunities beyond Jas Medical to expand revenue streams and establish a sustainable presence in the healthcare sector.
• The Company is actively evaluating potential acquisitions and will provide updates on material developments and funding strategies as appropriate.

3. Legal Proceedings Over Gainhealth Acquisition

• The Company has initiated legal proceedings in the High Court of Singapore against former directors, officers, and a facilitator over alleged breaches of fiduciary and statutory duties and unlawful conspiracy related to the Gainhealth Pte Ltd acquisition.
• Legal costs and potential recovery outcomes remain uncertain as the case is at an early stage. All legal expenses are being funded from the Group’s existing financial resources.

4. Material Uncertainty Relating to Going Concern

• The independent auditors have flagged material uncertainty regarding the Group’s ability to continue as a going concern:
  • The Group reported net liabilities of S\$1,471,861 and net current liabilities of S\$1,629,055.
  • The Company itself reported net liabilities of S\$2,278,958 and net current liabilities of S\$2,344,618.
  • A net loss of S\$1,252,759 and net operating cash outflows of S\$937,764 were recorded for FY2025.
• The Board asserts the going concern basis remains appropriate, citing:
  • Ongoing cost management initiatives.
  • Continued financial support from the controlling shareholder for at least 12 months (via an unconditional written undertaking to provide funds as needed).
  • Availability of S\$550,000 in loan facilities from the controlling shareholder.
  • Refinancing of S\$750,000 in maturing borrowings.
• The controlling shareholder’s support is not legally binding in the form of a fixed facility but is a written, unconditional undertaking and extends to existing shareholder loans (which will not be called for repayment until the Group is financially able).
• The Board has benchmarked financing terms and regards the current interest rates (15% p.a. on unsecured loans) as the best available under prevailing circumstances, but sees these as interim measures. The Company continues to seek better financing options and may consider both equity and debt to improve liquidity and capital structure.

5. Board Composition and Corporate Governance

• Following management changes in March 2025, the Board comprises three directors: one Executive Chairman and two Independent Directors, all of whom serve on all Board committees.
• Non-Compliance with Governance Code:
  • The current structure does not fully comply with the 2018 Code of Corporate Governance, notably having an Executive Director on the Audit and Remuneration Committees.
• The Board, through its Nominating Committee, reviews its size and composition at least annually, balancing governance standards, business scale, and cost/resource constraints.
• The Board aims to appoint an additional Independent Director by 2028 or earlier, contingent on financial resources and suitable candidate availability. The search is ongoing, with the Board leveraging professional networks and focusing on skills, experience, and diversity.

Potential Price-Sensitive and Investor-Relevant Highlights

• Jas Medical’s underperformance versus acquisition assumptions is negative for future earnings prospects and may weigh on valuation.
• The legal action over the Gainhealth acquisition introduces uncertainty over possible recoveries or further costs.
• The material uncertainty on going concern, high cost of debt, and reliance on controlling shareholder support are significant risks that may impact investor confidence and share price.
• Delayed compliance with corporate governance standards may affect investor perception and the Company’s reputation.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should carefully read Meta Health Limited’s official disclosures and consult their professional advisors before making any investment decisions. The information herein is based on Company announcements as of 23 April 2026 and may be subject to change.

View Meta Health Historical chart here